Casdin Capital
Latest statistics and disclosures from Casdin Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are RVMD, RLAY, WGS, BLFS, ILMN, and represent 63.16% of Casdin Capital's stock portfolio.
- Added to shares of these 10 stocks: WGS (+$48M), RLAY (+$30M), Parabilis Medicines (+$18M), SION (+$18M), SRRK (+$17M), GRAL (+$17M), PSNL (+$13M), SRPT (+$8.4M), ANL (+$8.2M), QURE (+$6.9M).
- Started 6 new stock positions in SRPT, Kardigan Ord, SION, EDIT, Parabilis Medicines, QURE.
- Reduced shares in these 6 stocks: TXG (-$47M), BLFS (-$37M), GH (-$20M), QGEN (-$14M), TEM (-$13M), MLTX (-$8.4M).
- Sold out of its positions in MLTX, TEM, QGEN.
- Casdin Capital was a net buyer of stock by $59M.
- Casdin Capital has $2.0B in assets under management (AUM), dropping by 51.28%.
- Central Index Key (CIK): 0001534261
Tip: Access up to 7 years of quarterly data
Positions held by Casdin Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Casdin Capital
Casdin Capital holds 43 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Revolution Medicines (RVMD) | 24.2 | $483M | 2.6M | 187.28 |
|
|
| Relay Therapeutics (RLAY) | 15.0 | $300M | +11% | 16M | 18.71 |
|
| Genedx Holdings Corp Com Cl A (WGS) | 12.7 | $255M | +23% | 3.7M | 68.65 |
|
| Biolife Solutions Com New (BLFS) | 6.6 | $132M | -21% | 4.7M | 28.24 |
|
| Illumina (ILMN) | 4.7 | $93M | 530k | 175.83 |
|
|
| D Fluidigm Corp Del (LAB) | 3.7 | $73M | 89M | 0.82 |
|
|
| Structure Therapeutics Sponsored Ads (GPCR) | 3.2 | $63M | 1.2M | 53.67 |
|
|
| Denali Therapeutics (DNLI) | 2.6 | $53M | +11% | 2.0M | 25.72 |
|
| Neurogene (NGNE) | 2.4 | $49M | +8% | 1.5M | 31.45 |
|
| Beam Therapeutics (BEAM) | 2.3 | $46M | 1.4M | 34.32 |
|
|
| 10x Genomics Cl A Com (TXG) | 2.0 | $40M | -53% | 1.1M | 38.34 |
|
| Scholar Rock Hldg Corp (SRRK) | 1.8 | $37M | +90% | 665k | 55.00 |
|
| Personalis Ord (PSNL) | 1.7 | $34M | +59% | 2.6M | 13.40 |
|
| Grail (GRAL) | 1.6 | $33M | +108% | 480k | 68.27 |
|
| Guardant Health (GH) | 1.4 | $28M | -41% | 185k | 150.03 |
|
| Maze Therapeatics (MAZE) | 1.3 | $25M | +11% | 844k | 29.84 |
|
| Hims & Hers Health Com Cl A (HIMS) | 1.2 | $24M | 700k | 34.67 |
|
|
| Alnylam Pharmaceuticals (ALNY) | 1.1 | $23M | 75k | 301.03 |
|
|
| Taysha Gene Therapies Com Shs (TSHA) | 1.1 | $22M | 3.3M | 6.81 |
|
|
| Agomab Therapeutics Nv Sponsored Ads (AGMB) | 1.0 | $20M | 1.6M | 12.98 |
|
|
| Septerna (SEPN) | 0.9 | $19M | 553k | 33.49 |
|
|
| Parabilis Medicines | 0.9 | $18M | NEW | 646k | 27.37 |
|
| Sionna Therapeutics (SION) | 0.9 | $18M | NEW | 400k | 43.99 |
|
| Veracyte (VCYT) | 0.8 | $16M | 276k | 58.73 |
|
|
| Adlai Nortye Sponsored Ads (ANL) | 0.7 | $14M | +132% | 1.3M | 11.50 |
|
| Prime Medicine (PRME) | 0.6 | $12M | 3.2M | 3.69 |
|
|
| Absci Corp (ABSI) | 0.6 | $11M | 973k | 11.59 |
|
|
| Quest Diagnostics Incorporated (DGX) | 0.5 | $11M | 50k | 211.95 |
|
|
| Sarepta Therapeutics (SRPT) | 0.4 | $8.4M | NEW | 470k | 17.97 |
|
| Uniqure Nv SHS (QURE) | 0.3 | $6.9M | NEW | 150k | 46.06 |
|
| Intellia Therapeutics (NTLA) | 0.3 | $6.0M | 355k | 16.92 |
|
|
| Moderna (MRNA) | 0.3 | $5.3M | 75k | 70.03 |
|
|
| Disc Medicine (IRON) | 0.2 | $4.8M | 65k | 73.14 |
|
|
| Monte Rosa Therapeutics (GLUE) | 0.2 | $4.5M | 186k | 24.20 |
|
|
| Century Therapeutics (IPSC) | 0.2 | $3.0M | 1.2M | 2.45 |
|
|
| Contineum Therapeutics Cl A (CTNM) | 0.1 | $2.4M | 148k | 16.39 |
|
|
| Bridgebio Oncology Therapeut Com New (BBOT) | 0.1 | $2.2M | 282k | 7.62 |
|
|
| Editas Medicine (EDIT) | 0.1 | $1.4M | NEW | 445k | 3.24 |
|
| Pacific Biosciences of California (PACB) | 0.1 | $1.2M | 724k | 1.68 |
|
|
| Kardigan Ord | 0.1 | $1.2M | NEW | 50k | 23.85 |
|
| Recursion Pharmaceuticals In Cl A (RXRX) | 0.0 | $607k | 165k | 3.67 |
|
|
| Ginkgo Bioworks Holdings Cl A New (DNA) | 0.0 | $362k | 37k | 9.91 |
|
|
| Tenaya Therapeutics (TNYA) | 0.0 | $268k | 362k | 0.74 |
|
Past Filings by Casdin Capital
SEC 13F filings are viewable for Casdin Capital going back to 2015
- Casdin Capital 2026 Q2 filed Aug. 14, 2026
- Casdin Capital 2026 Q1 filed May 15, 2026
- Casdin Capital 2025 Q4 filed Feb. 17, 2026
- Casdin Capital 2025 Q3 filed Nov. 14, 2025
- Casdin Capital 2025 Q2 filed Aug. 14, 2025
- Casdin Capital 2025 Q1 filed May 15, 2025
- Casdin Capital 2024 Q4 filed Feb. 14, 2025
- Casdin Capital 2024 Q3 filed Nov. 14, 2024
- Casdin Capital 2024 Q2 restated filed Oct. 18, 2024
- Casdin Capital 2024 Q2 filed Aug. 14, 2024
- Casdin Capital 2024 Q1 filed May 15, 2024
- Casdin Capital 2023 Q4 filed Feb. 14, 2024
- Casdin Capital 2023 Q3 filed Nov. 14, 2023
- Casdin Capital 2023 Q2 filed Aug. 14, 2023
- Casdin Capital 2023 Q1 filed May 15, 2023
- Casdin Capital 2022 Q4 filed Feb. 14, 2023